Research analysts at Stifel Nicolaus started coverage on shares of Sionna Therapeutics (NASDAQ:SION - Get Free Report) in a note issued to investors on Tuesday, MarketBeat reports. The firm set a "buy" rating and a $32.00 price target on the stock. Stifel Nicolaus' price objective indicates a potential upside of 96.68% from the company's current price.
Separately, Guggenheim assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday. They issued a "buy" rating and a $45.00 price objective on the stock.
View Our Latest Report on Sionna Therapeutics
Sionna Therapeutics Stock Up 4.0 %
Shares of NASDAQ SION traded up $0.62 during mid-day trading on Tuesday, hitting $16.27. The stock had a trading volume of 327,316 shares, compared to its average volume of 225,817. Sionna Therapeutics has a 1 year low of $13.20 and a 1 year high of $25.19.
About Sionna Therapeutics
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
Further Reading
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
